We are analyzing https://link.springer.com/chapter/10.1007/978-3-319-13150-4_7.

Title:
Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia | SpringerLink
Description:
Waldenström Macroglobulinemia (WM) is a rare B-cell lymphoma characterized by the uncontrolled accumulation of malignant lymphoplasmacytic cells, mainly in the bone marrow, and monoclonal IgM production. Despite its rarity, our understanding of the biology of...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, pubmed, macroglobulinemia, article, cas, lymphoma, waldenstrom, waldenstroms, treon, blood, patients, rituximab, chapter, therapy, oncol, clin, trial, relapsed, treatment, myd, central, phase, ghobrial, cancer, clinical, survival, bortezomib, study, castillo, lymphoplasmacytic, hunter, myeloma, waldenström, yang, mutation, results, refractory, privacy, cookies, content, analysis, information, publish, research, nonhodgkin, hematol, multicenter, springer, european,

Topics {✒️}

org/professionals/physician_gls/pdf/waldenstroms tlr/il-1r signalling month download article/chapter autologous stem-cell transplantation allogeneic stem-cell transplantation dana-farber cancer institute myd88-irak4-irak2 complex population-based prognostic factors b-cell lymphomagenesis treon sp privacy choices/manage cookies tufts medical center device instant download mantle-cell lymphomas waldenström macroglobulinemia chapter editor information editors malignant lymphoplasmacytic cells lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia receptor-dependent responses phosphatidylinositol 3-kinase-δ gertz ma marginal zone lymphoma lymphoma working party consensus panel recommendations neuropathy-sparing approach oral mammalian target rapamycin inhibitor everolimus mtor inhibitor everolimus good partial response comprehensive seer analysis furman rr higher cohort doses harvard medical school multicenter clinical trial bruton tyrosine kinase clinical features observed small somatic deletions population-based study conditions privacy policy current therapeutic options current evidence supporting marker highly characteristic nccn guidelines european economic area van wier sa related lymphoid neoplasms european myeloma network monoclonal igm production san miguel jf consecutive treatment eras

Schema {🗺️}

ScholarlyArticle:
      headline:Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia
      pageEnd:195
      pageStart:177
      image:https://media.springernature.com/w153/springer-static/cover/book/978-3-319-13150-4.jpg
      genre:
         Medicine
         Medicine (R0)
      isPartOf:
         name:Non-Hodgkin Lymphoma
         isbn:
            978-3-319-13150-4
            978-3-319-13149-8
         type:Book
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jorge J. Castillo
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Irene M. Ghobrial
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Steven P. Treon
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Waldenström Macroglobulinemia, MYD88, CXCR4, Biology, Therapy, Survival
      description:Waldenström Macroglobulinemia (WM) is a rare B-cell lymphoma characterized by the uncontrolled accumulation of malignant lymphoplasmacytic cells, mainly in the bone marrow, and monoclonal IgM production. Despite its rarity, our understanding of the biology of this disease has improved significantly in recent years with the identification of recurrent mutations in the MYD88 and CXCR4 genes. Based on the diversity of clinical features observed in WM patients, therapy should be highly personalized having into account several factors such as age, co-morbidities, IgM levels, and presence of hyperviscosity, coagulopathy, cryoglobulinemia, or cold agglutinin disease. In this chapter, we review the recent advances in the biology of WM and the current therapeutic options for untreated and relapsed WM patients. Finally, we discuss the role of prognostic factors and current evidence supporting an improvement in the survival of WM patients in the last decade.
      datePublished:2015
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Non-Hodgkin Lymphoma
      isbn:
         978-3-319-13150-4
         978-3-319-13149-8
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jorge J. Castillo
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Irene M. Ghobrial
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Steven P. Treon
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(199)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

CDN Services {📦}

Pbgrd

5.29s.

LINK . SPRINGER . COM {}